It just occurred too me that Eastern and I believe NGN (I think they have been involved before spico) probably have the inside scoop on the zen3694 trial. If there really is the opportunity to sell zen3694 at an early stage because it is showing very strong results on mCRPC results then Eastern and NGN would be quite pleased to take some cash if at the right price?
In terms of liquidity I do not see Don doing an IPO even though he stated that on 2 occassions. I don't feel it would generate a significant share price given the early stage development and the high risk.
Better to keep it private and if it generates spectacular results;
- It begins to validate an entirely new approach to cancers (I recognise other companies have been trying epigenetics on cancers but I don't recall any successes to date. If there were successes it would have been all over the news).
- It may begin to generate interest from Pfizer and others. The large BPs need to begin to fill their pipelines with new drugs and they have a ton of money to do it.
Anyway, I'm just rambling. It sure would be fantastic for zen3694 to hit a home run as we wait another 2 years for apabetalone to prove itself. I believe a zen3694 homerun would have a halo effect on RVX...JMO.
GLTA
Toinv
